GlassScriptPhysician profile
Emily M Hinchcliff
NPI 1558707877
$62,434.37
in general payments reported to CMS, 2019-2025
13 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2021: $445 · 2022: $268 · 2023: $238 · 2024: $29K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $5,950 · Food and Beverage: $3,060 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,878.00 |
| Travel and Lodging | $5,949.75 |
| Food and Beverage | $3,060.39 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59,747.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $774.67 | 2021-2025 | Lynparza, Enhertu |
| Clovis Oncology, INC. | $412.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $281.54 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Tesaro, INC. | $240.42 | 2019 | |
| Stryker Corporation | $224.92 | 2021 | |
| Foundation Medicine, INC. | $205.85 | 2022-2023 | |
| Baxter Healthcare | $131.23 | 2021-2025 | Floseal |
| Genentech USA, INC. | $126.78 | 2019 | |
| Seagen INC. | $104.15 | 2019 | |
| On Target Laboratories, INC | $97.42 | 2025 | Cytalux |
| Glaxosmithkline, LLC. | $87.19 | 2023-2025 | Jemperli, Zejula |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hinchcliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.